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Abstract
The aim of this case report is to depict conservative symptomatic treatment in a patient with anorex-
ia-cachexia syndrome and to discuss the possible interventions for such patients. The mechanisms and 
clinical management of anorexia-cachexia syndrome are discussed. A 79-year-old woman was admitted to 
hospice-at-home care due to the progression of an inoperable cardia cancer, with symptoms of dysphagia, 
cachexia and weakness. Due to the advanced stage of the cancer, general poor condition and concomitant 
disease (Parkinson’s disease, diabetes mellitus, myocardial infarction), the patient did not qualify for surgery 
or chemotherapy. As the patient refused a gastrostomy, she was treated with symptomatic measures (phar-
macotherapy) with the important contribution of a surgeon who several times performed endoscopic cardia 
dilatation, which enabled her feeding through the oral route until death and improved the patient’s quality 
of life. Due to social problems, low food intake, dehydration, electrolyte imbalance and the consideration of 
parenteral nutrition, the patient was admitted to the inpatient unit, where she died suddenly after five days.
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Introduction
Cancer anorexia-cachexia syndrome (CACS) 
is common in patients with advanced stages of the 
disease and 55–70% of these patients usually suf-
fer from the symptoms. According to estimations, 
cachexia is the cause of death in 30% of patients with 
advanced cancer [1]. Unfortunately, due to common 
and unspecific symptoms, it is difficult to define 
CASC precisely. The term “cachexia” derives from 
Greek: kakos — bad and heksis — state, condition. 
Cachexia is best defined as a syndrome connected 
with progressive weight loss, weakness, loss of ap-
petite and metabolic disturbances with impaired 
function of the immunology system. It is associated 
with loss of muscle mass, characterized by increased 
catabolism of skeletal muscle and decreased protein 
synthesis [2]. CACS is a cytokine-driven dysregulation 
of the peripheral signals (mainly leptin, ghrelin and 
serotonin) which play a central role in unbalanc-
ing the orexigenic and anorexigenic signals and 
leads to decreased food intake and an increase 
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of resting energy expenditure (primary cachexia). 
However, when the disease disrupts the integrity 
of the gastrointestinal tract, development of CACS 
is called secondary cachexia [3]. The final outcome 
of CACS is multiple organ failure, water-electrolyte 
imbalance, anaemia and hormonal dysfunction [4]. 
From the clinical point of view, quality of life (QOL) 
deterioration due to weakness and a negative influ-
ence on the psychological condition of a patient 
is one of the important features of the syndrome 
[5]. The loss of weight may cause changes in body 
image which negatively influence patients’ social 
functioning. A poor sensation of well-being may also 
evoke a fear of dying, anger, depression, spiritual 
pain and the feeling of being a burden to relatives. 
Cachexia causes the loss of important values, such 
as work, social activity, avocation and dignity, and in 
consequence often the development of depression 
[6]. The aim of this article is to describe what pallia-
tive care can achieve for patients with CACS and to 
discuss the possible interventions in such patients.
Case report
A 79-year-old woman was admitted to a hos-
pice-at-home facility due to an inoperable cardia 
cancer with anorexia-cachexia syndrome. Her his-
tory revealed previous chronic atrophy and pharynx 
inflammation, myocardial infarction, pneumonia, 
Parkinson’s disease, diabetes type 2 and depression. 
The first symptoms (weakness, loss of weight, swal-
lowing difficulties and pain in the upper abdomen) 
dated from nine months before the diagnosis but 
the endoscopic investigations performed did not 
show cancer presence. In May 2008 repeated endos-
copy and contrast radiography revealed advanced 
adenocarcinoma of the stomach (G2). Stomach 
resection was attempted but abandoned due to 
local infiltration. Due to poor general condition 
and co-morbidities, she did not qualify for other 
oncological treatment. She persistently refused the 
insertion of nutritional gastrostomy, jejunostomy or 
stenting. In June 2008 she was referred to the local 
hospice-at-home service. She was treated sympto-
matically until December 2008. Endoscopic cardia 
dilatation was repeated bi-monthly, which enabled 
her to feed orally until the end. On admission to 
hospice-at-home she had had a weight loss of 20 
kg since the first symptoms, and complained of 
mild to moderate upper abdominal pain (3–4 on 
a numerical rating scale: 0 — no pain, 10 — the 
most severe pain), belching after meals, fatigue, lack 
of energy, lack of appetite, constipation, nausea, 
hiccups, flatulence, dry mouth, decreased taste of 
food and dysphagia. She also reported insomnia, 
difficulties in concentration, irritability, worrying, 
depressive mood, the lack of an aim in life, anxiety, 
poor QOL and poor general well-being, and dysp-
noea on slight effort. She needed assistance in all 
her activities and was confined to her flat. On physi-
cal examination, her general condition was poor. 
There was no confusion. A pathological mass in the 
middle upper abdomen, enlarged liver and a mod-
erate leg oedema were found. Her performance 
status was ECOG 3–4, Karnofsky 40–50. The patient 
was wearing incontinence pads. She ate only mixed, 
homogenized foods five times a day and her fluid 
intake was estimated to be approximately 1 L a day.
Her abdominal pain, nausea and vomiting were 
initially treated with tramadol 20 mg and hyos-
cine buthylbromide 8 mg SC every 4 hr with 8-hr 
intervals during the night. Other drugs comprised 
dexamethasone, initially 4 mg increased to 8 mg SC 
OD in the morning; Madopar 62.5 mg BD for her 
Parkinson’s disease; Clomipramine 62.5 mg OD for 
her depressive mood and omeprazole 20 mg OD. 
After three months of treatment, the dexamethasone 
dose was reduced to 4 mg OD. The dose of trama-
dol was increased to 50 mg per single dose due to 
pain exacerbation. Due to limited fluid intake for 
a few days, she received 500 ml of normal saline or 
500 ml multi-electrolyte fluid OD. Her bowel function 
was maintained with glycerine suppositories PRN. In 
the case of nausea or vomiting, she was prescribed 
promethazine 12.5 mg SC. She received hydrochloro-
thiazide 25 mg with amiloride 5 mg for leg oedema 
with good effect. Her treatment was continued; 
however, all drugs were administered via plastic SC 
needles, as formerly inserted “butterfly” metallic 
needles caused several inflammatory local reactions. 
She performed some light exercises once a week with 
a physiotherapist: increasing efficiency, active exer-
cises, breathing exercises, massage of lower extremi-
ties, walking with assistance and isometric exercises. 
She was visited by a nurse three times a week and 
a physician every two weeks from the home pallia-
tive care team. She received good support from her 
husband and from the three adult daughters.
In spite of acceptable symptom control, she drank 
0.5 L of fluids per day and her anorexia was exac-
erbated. Her husband was exhausted from caring 
for the patient. She was considered for parenteral 
nutrition due to low food intake and at the be-
ginning of December 2008 she was admitted to 
the palliative care inpatient unit. Laboratory re-
sults showed dehydration, hypoproteinaemia, hy-
www.advpm.eu 131
Wojciech Leppert, Anorexia-cachexia in advanced gastric cancer
poalbuminaemia and electrolyte imbalance: hypoka-
laemia 2.7 mmol/L (3.7–5.2) and hypomagnesaemia 
1.5 mg/dl (1.95–2.95). Her CRP was 131 mg/L (0.1–5). 
She continued the home drug regimen with added 
intravenous fluids (1.5 L/day with potassium and 
magnesium) with dexamethasone 4 mg IV once daily. 
The water and electrolyte imbalance was corrected 
and a central venous access created. However, after 
a five-day stay in the palliative care unit, she died 
suddenly before starting parenteral nutrition. The 
cause of death was attributed to severe cachexia.
Discussion
This case report is an illustration of problems en-
countered during the care of a patient with advanced 
gastric cancer and CACS. The patient complained 
of several symptoms associated with gastric cancer 
(nausea, epigastric pain with belching and lack of 
appetite) but also of the delayed diagnosis and as-
sociated spiritual pain. The latter problem was asso-
ciated with the fact that the investigations performed 
during a year before diagnosis establishment did not 
show cancer presence. In addition, the progressive 
CACS resulted in intense psychological distress. De-
spite support from the home palliative care team, the 
family nurse and all family members, it was necessary 
to admit the patient to the inpatient palliative care 
unit for respite care, as her husband was exhausted 
from taking care of the patient. Although the patient 
did not agree to a gastrostomy and/or stent insertion 
[7], several oesophagus and cardia endoscopic dila-
tations allowed the maintenance of feeding orally. 
These interventions can improve patient QOL [8]. 
The management of patients with advanced GI 
tumours is a challenge for clinicians as, apart from 
primary cachexia, the secondary malnutrition asso-
ciated with cancer progression and symptoms of GI 
obstruction contribute to the CACS development; 
this seems to have been the case in our patient [9]. 
The patient was treated with corticosteroids and did 
not receive progestagens because of the secondary 
cachexia, dysphagia and nausea. The psychological 
and spiritual distress added to this and, apart from 
comprehensive medical management, psychosocial 
and spiritual support is needed for such patients and 
their families [10]. Apart from the support of the 
nurses, physicians and a psychologist, the patient 
performed light exercises intended for the decrease 
of fatigue intensity and the improvement in func-
tioning and mood, with some benefit achieved 
as reported in the literature [11]. As mentioned, 
the patient was admitted to the palliative care unit 
for respite care for her husband and considered for 
a parenteral nutrition programme due to significant 
exacerbation of her anorexia. However, due to sud-
den death, this approach was not introduced and 
she only received intravenous fluids. The cause of 
this unexpected patient death was attributed to se-
vere cachexia. However, as the patient died suddenly, 
other potential pathologies, such as myocardial 
infarction, heart failure exacerbated by fluid admi-
nistration, pulmonary embolism, reflex bradycardia 
secondary to oesophagus distension, and infection 
from the central catheter, should be considered. 
Unfortunately, this can only be speculated upon, 
as an autopsy was not conducted.
Cachexia often accompanies loss of appetite 
(anorexia) and weakness (asthenia) and is called 
cachexia-anorexia-asthenia syndrome by some [12]. 
The main symptoms of CACS are loss of appe-
tite, loss of weight, early satiety, general weakness, 
frequent fatigue, decrease in immunology system 
function and metabolic disorders [13, 14]. Cachexia 
management comprises pharmacotherapy and nu-
tritional support, anticancer treatment (if possible), 
the management of numerous symptoms that may 
contribute to cachexia development, as well as psy-
chosocial and spiritual support for the patient and 
family [15]. The aim of the treatment is to inhibit 
anorexia and weight loss as quickly as possible, to 
sustain a good sensation of well-being and general 
condition, and to inhibit or delay disturbances in 
the immunology system. The application of light 
exercises may decrease fatigue intensity and improve 
functioning and patient mood [11]. The treatment 
should start with information on CACS and its man-
agement possibilities being provided to the patient 
and family. Another aim is appetite improvement 
through the treatment of the reversible causes of 
appetite loss. Several factors may cause lack of ap-
petite, such as dry and sore mouth, the adverse 
effects of drugs (opioids, antycholinergics, SSRIs, 
antibiotics), the adverse effects of chemotherapy 
and radiotherapy, especially for the head and neck 
regions, inadequate pain relief, and other symptoms, 
such as dyspnoea, nausea and vomiting [5]. In the 
case of mechanical obstruction of the upper GI tract, 
a gastrostomy or jejunostomy may be considered, 
provided the patient has a relatively good general 
condition [16]. A stent [7] or nasogastric tube may 
be inserted, although the latter should be limited to 
a short period of time (4–6 weeks) [17].
The drugs that show efficacy in the pharmacother-
apy of CACS are progestagens (megestrol acetate, 
medroxyprogesterone acetate) [18]. However, these 
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agents increase body weight, improve well-being, 
appetite and quality of life, whilst failing to increase 
lean body mass, an important target of CACS man-
agement [19]. Other commonly-used drugs are cor-
ticosteroids (dexamethasone, prednisolone, meth-
ylprednisolone) and prokinetics (metoclopramide, 
domperidone). However, similarly to cannabinoids, 
their role is still not clearly established [20] and the 
latter are unavailable in Poland. Other drugs are be-
ing assessed in clinical trials. Preliminary results have 
demonstrated that a combination of megestrol ac-
etate and olanzapine may be much more effective 
than progestagens administered alone [21]. The 
administration of selective COX-2 inhibitors (e.g. 
celecoxib), oxandrolone, thalidomide, EPA (eicosapa-
ntaenoic acid), ghrelin mimetics, insulin, and ostarine 
(the first-class selective androgen receptor modula-
tor SARM) are newer and promising therapies. An 
experimental approach to CACS management in mice 
comprises myostatin antagonism, antagonists of 
the melanocortin MC4 receptors that can be ad-
ministered orally, CD+ T cells and branched-chained 
amino acids [22]. A combination of different ap-
proaches is more effective than a single method of 
treatment. A combination of megestrol acetate with 
ibuprofen improved quality of life and was more ef-
fective than megestrol with placebo in patients with 
weight loss in the course of gastrointestinal cancer 
[23]. Preliminary results achieved in 125 patients in 
a phase III study indicate that combining progesta-
gens with EPA, L-carnitine and thalidomide was more 
effective than using any of these agents alone [24].
The nutritional support is also an important part 
of CACS management, especially for patients with GI 
tract tumours and secondary cachexia. For those who 
can use the oral route, the addition of high energy 
supplements may improve the calorie intake. In the 
case of dysphagia, enteral feeding with oesopha-
gus or cardia tumour stents should be considered 
[25]. In patients with GI obstruction, parenteral 
nutrition may be considered but it is associated with 
numerous possible complications and high financial 
costs [26, 27]. In a recent study parenteral nutri-
tion in patients with incurable GI cancer prolonged 
survival but with frequent infectious complications; 
there is no tool to predict which patients may receive 
benefits which outweigh the complications [28].
Future studies may address the cytokine genetic 
polymorphisms associated with CACS. In 203 pa-
tients with gastro-oesophageal cancer, single nucle-
otide polymorphism was performed. Compared with 
other genotypes, the IL-10 GG genotype retained an 
independent association in determining the extent 
of weight loss upon multivariate analysis (95% CI: 
0.52, 3.43; p = 0.008). Possession of the GG allele 
was associated with a 2.3 times increased risk of 
developing cachexia (95% CI: 1.2, 4.3; p = 0.014). It 
was suggested that the IL-10 genotype of a patient 
can influence the development of cachexia among 
patients with gastroesophageal malignancy [29]. 
In a preliminary study, 471 patients with non-small 
cell lung cancer were explored as to whether any of 
the 22 single nucleotide polymorphisms of inflam-
matory cytokines (IL-1 beta, IL-1RN, IL-6 and tumour 
necrosis factor alpha) is associated with anorexia 
and weight loss. Only tumour necrosis factor alpha 
rs800629 was associated with anorexia (p < 0.001). 
Cancer stage and the patient’s age were the only 
predictors of survival [30].
The management of CACS remains a challenge 
for palliative care teams. New, more efficient thera-
pies are eagerly awaited, as current available meas-
ures are often ineffective. A holistic approach with 
medical, nutritional, psychosocial and spiritual sup-
port for patients suffering from CACS is currently 
recommended.
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